Related Experiment Videos
Radiotherapy for t3 prostate cancer.
Andrew Bayley1, Mary K Gospodarowicz
1Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.
Current Urology Reports
|May 21, 2003
Summary
Advances in T3 prostate cancer management now favor combined hormone and radiation therapy over radiation alone, improving survival. Dose escalation in radiotherapy enhances local control and reduces toxicity for better patient outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Prostate Cancer Research
Background:
- Significant advancements in T3 prostate cancer management over the last decade.
- Established superiority of combined hormone and radiation therapy (HRT) over radiation therapy (RT) alone through Phase III trials.
Purpose of the Study:
- To review the current role of radiation therapy in managing clinical T3 prostate cancer.
- To contextualize radiation therapy within the spectrum of available treatment options for T3 prostate cancer.
Main Methods:
- Review of Phase III randomized studies comparing treatment modalities.
- Analysis of radiotherapy dose escalation techniques, including conformal radiotherapy.
- Evaluation of treatment outcomes focusing on local control, toxicity, and survival prolongation.
Main Results:
- Combined hormone and radiation therapy demonstrates superior outcomes compared to radiation therapy alone.
- Radiotherapy dose escalation, particularly with conformal techniques, improves local tumor control.
- Dose escalation also leads to a reduction in treatment-related toxicity.
Conclusions:
- Contemporary management of T3 prostate cancer has shifted towards earlier interventions aimed at prolonging survival.
- Radiation therapy, especially with optimized techniques and combined modalities, plays a crucial role in achieving better outcomes for T3 prostate cancer patients.